Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

11/4/24 12:09:32 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ESPR alert in real time by email

SC 13G/A 1 UnitedStates_13G__EsperionTh.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Esperion Therapeutics Inc (Title of Class of Securities) Common Stock (CUSIP Number) 29664W105 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 29664W105 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 145,274 (7) Sole dispositive power 12,834,409 (8) Shared dispositive power 208,668 (9) Aggregate amount beneficially owned by each reporting person 13,043,077 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 6.64% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Esperion Therapeutics Inc Item 1(b) Address of issuer's principal executive offices: 3891 Ranchero Drive Suite 150 Ann Arbor, MI 48108 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 29664W105 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 13,043,077 (b) Percent of class: 6.64% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 13,043,077 (b) Percent of class: 6.64% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 145,274 (iii) Sole power to dispose or to direct the disposition of: 12,834,409 (iv) Shared power to dispose or to direct the disposition of: 208,668 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired

Get the next $ESPR alert in real time by email

Recent Analyst Ratings for

$ESPR

Date	Price Target	Rating	Analyst
12/18/2024	$4.00	Neutral	Goldman
12/17/2024	$8.00	Overweight	Cantor Fitzgerald
6/20/2024	$2.50	Neutral → Underperform	BofA Securities
1/3/2024		Buy → Neutral	BofA Securities
11/20/2023		Neutral	JP Morgan
8/1/2023		Under Perform → Market Perform	Northland Capital
6/15/2023	$1.25 → $4.00	Underperform → Buy	BofA Securities
3/16/2023	$1.00	Market Perform → Under Perform	Northland Capital

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for $ESPR

$ESPR FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

$ESPR Leadership Updates

Live Leadership Updates

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Esperion Appoints Robert E. Hoffman to Board of Directors

$ESPR Large Ownership Changes

This live feed shows all institutional transactions in real time.